Vicente Navarro-López, Asunción Martínez-Andrés, Ana Ramírez-Boscá, Beatriz Ruzafa-Costas, Eva Núñez-Delegido, Miguel A. Carrión-Gutiérrez, David Prieto-Merino, Francisco Codoñer-Cortés, Daniel Ramón-Vidal, Salvador Genovés-Martínez, Empar Chenoll-Cuadros, José M. Pérez-Orquín, José A. Picó-Monllor, Sara Chumillas-Lidón
DOI: 10.2340/00015555-3305

The aim of this 12-week randomized, double-blind, placebo-controlled trial was to determine the efficacy and safety of a probiotic mixture in the reduction of psoriasis severity. Ninety 18–70-year-old adults with plaque psoriasis were randomized into probiotic and placebo groups. At 12-week follow-up, 66.7% of patients in the probiotic group and 41.9% in the placebo group showed a reduction in Psoriasis Area and Severity Index of at least 75% (p < 0.05). A clinically relevant difference was observed in Physician Global Assessment index: 48.9% in the probiotic group achieved a score of 0 or 1, compared with 30.2% in the placebo group. The results of follow-up 6 months after the end of the study showed a lower risk of relapse after the intake of the probiotic mixture. Analysis of gut microbiota confirmed the efficacy of the probiotic in modulation of the microbiota composition.

This clinical trial evaluated the effect of a probiotic mixture as coadjutant treatment together with topical steroids in 90 patients with plaque psoriasis. The results showed a larger reduction in the score of severity indexes in the probiotic group compared with the placebo group. Gut microbiota analysis demonstrated the efficacy of the probiotic in modulation of the composition of the microbiota. After the end of the probiotic or placebo intake, patients were followed-up for 6 months. The results showed a lower risk of relapse in patients in the probiotic group.

Erratum: Efficacy and Safety of Oral Administration of a Mixture of Probiotic Strains in Patients with Psoriasis: A Randomized Controlled Clinical Trial

Figure S3
Table SI
Figure S1
Figure S2